Sep 19, 2023 7:00 am EDT Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry
Sep 14, 2023 7:00 am EDT TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus
Sep 12, 2023 7:00 am EDT Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
Sep 9, 2023 8:00 pm EDT Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences’ IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression
Sep 8, 2023 4:30 pm EDT TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus
Sep 6, 2023 7:00 am EDT Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023
Aug 7, 2023 7:00 am EDT New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
Aug 1, 2023 7:00 am EDT Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference
